Association Between Age at Diagnosis and the Presence of EGFR Mutations in Female Patients with Resected Non-small Cell Lung Cancer
Association Between Age at Diagnosis and the Presence of EGFR Mutations in Female Patients with Resected Non-small Cell Lung Cancer
复制标题
DOI：
10.1097/jto.0b013e3181f38816
复制
发表时间：
2010-12-01
影响因子：
20.4
通讯作者：
Na, Im Il
中科院分区：
文献类型：
--
作者：
Choi, Yoon Hee;Lee, Jin Kyung;Na, Im Il
背景：我们先前的报告显示，年龄和吉非替尼治疗的女性非小细胞肺癌(NSCLC)患者的预后之间存在关联。根据年龄，关于表皮生长因子受体(EGFR)突变的存在只进行了有限数量的分子研究。方法：对1992年1月至2002年12月在韩国肿瘤中心医院接受手术切除的98例女性非小细胞肺癌患者的石蜡标本进行回顾性研究。使用蝎子扩增耐药突变系统检测EGFR突变。结果：大多数研究人群包括从不吸烟(84%)和腺癌患者(82%)。确诊时的年龄从34岁到74岁(中位数57岁)。当使用中位年龄作为分界值时，老年患者比年轻患者更有可能发生表皮生长因子受体基因突变(70%比39%；p=0.004)。在控制了组织学、吸烟史和分期的影响后，年龄仍然是表皮生长因子受体突变的重要预测因素(优势比，4.03；95%可信区间，1.61-10.09；p=0.003)。结论：我们的数据表明，女性非小细胞肺癌患者确诊时的年龄可能与表皮生长因子受体突变的频率有关，这是预后良好的有力指标。
Background: Our previous report showed an association between age and outcome in gefitinib-treated female patients with non-small cell lung cancer (NSCLC). Only limited numbers of molecular studies have been performed with respect to the presence of epidermal growth factor receptor (EGFR) mutations according to age. This retrospective study was performed to evaluate a possible association between age at the time diagnosis and the presence of EGFR mutations in female patients with NSCLC.Methods: Tumor specimens were collected retrospectively from paraffin blocks of 98 female patients with primary NSCLC who underwent surgical resection between January 1992 and December 2002 at the Korea Cancer Center Hospital. To detect EGFR mutations, a Scorpion Amplified Refractory Mutation System was used.Results: Most of the study population comprised never smokers (84%) and patients with adenocarcinoma (82%). The age at the time of diagnosis ranged from 34 to 74 years (median, 57 years). When the median age was used as a cutoff value, older patients were more likely to have EGFR mutations than younger patients (70 versus 39%; p = 0.004). After controlling for the effects of histology, smoking history, and stage, age remained a significant predictor for EGFR mutations (odds ratio, 4.03; 95% confidence interval, 1.61-10.09; p = 0.003).Conclusions: Our data suggest that age at the time of diagnosis in female patients with NSCLC may be associated with the frequency of EGFR mutations, a strong indicator for favorable outcomes.